This study is for men and women who have been diagnosed with primary biliary cholangitis (PBC), a chronic liver disease that slowly damages the bile ducts in the liver. This study will test the investigational/study drug Seladelpar.
Seladelpar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of PBC. However, this study is being conducted to further evaluate its safety and effectiveness.